EN
Home/Answers/Side effects
ALLAll countries Side effects and safety

What are the side effects of tirzepatide and semaglutide?

What we checked11 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

The most common side effects of tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) are nausea, diarrhoea, vomiting and constipation. In the US Zepbound trials, 56% had stomach side effects, against 30% on placebo. Most are mild or moderate and ease after the dose step-ups. Rarer risks include pancreatitis, gallbladder disease, kidney injury and severe allergic reactions.

Which side effects are most common?

Stomach side effects lead the list. In the US Zepbound weight trials, 56% of people on tirzepatide had them, against 30% on placebo.1

Depending on the dose, nausea affected 25% to 29% of people on tirzepatide (8% on placebo). Diarrhoea affected 19% to 23% (8%), constipation 11% to 17% (5%) and vomiting 8% to 13% (2%).1 In the US Wegovy label’s weight trials of semaglutide 2.4 mg, nausea affected 44% (16% on placebo). Diarrhoea affected 30% (16%), vomiting 24% (6%) and constipation 24% (11%).2 These figures come from separate trials. The US Wegovy label says rates from one drug’s trials cannot be directly compared with another’s.2

In SURMOUNT-5, a Lilly-funded head-to-head trial, nausea affected 43.6% on tirzepatide and 44.4% on semaglutide.11

Both labels also list stomach pain, indigestion, burping, reflux, bloating, wind, tiredness and dizziness.1,2 Headache affected 14% on Wegovy against 10% on placebo.2 Injection-site reactions affected 6% to 8% on Zepbound against 2% on placebo.1

Hair loss is listed too, and both US labels link it to weight loss. On Zepbound it was reported by 7.1% of women and 0.5% of men. On Wegovy 2.4 mg, it was reported by 3.3% of people, against 1% on placebo.1,2

How bad are they, and do they pass?

Most are mild or moderate. In the EU Mounjaro label’s weight trial, 61% of stomach side effects were mild and 35% moderate.3

The same label says nausea, vomiting and diarrhoea were more common during the dose step-ups. They then decreased over time.3 A Novo Nordisk-funded analysis of the STEP trials found semaglutide’s stomach side effects typically mild to moderate, non-serious and transient.5 Constipation lasted longest, with a typical bout of 47 days against 35 days on placebo.5

A minority stop treatment. In the US Zepbound trials, 4.8% to 6.7% of people stopped because of side effects, against 3.4% on placebo. Most stopped in the first few months, mostly because of stomach effects.1 On Wegovy, 6.8% stopped against 3.2% on placebo.2 Severe stomach side effects affected 1.7% to 3.1% on Zepbound against 1% on placebo.1 If a dose is not tolerated, the US Zepbound label suggests considering a lower maintenance dose.1

What are the rarer, serious risks?

The labels warn about pancreatitis, gallbladder disease, kidney injury from dehydration, severe allergic reactions and low blood sugar.1,2

Gallbladder inflammation affected 0.7% on Zepbound against 0.2% on placebo.1 Gallstones affected 1.6% on Wegovy injection against 0.7% on placebo.2 Confirmed pancreatitis was 0.2% in both the Zepbound and placebo groups of the weight trials.1 Kidney injury has been reported after approval, mostly in people dehydrated by nausea, vomiting or diarrhoea.1 Our country side-effects guides cover each country’s label.

Low blood sugar is mainly a risk alongside other diabetes medicines. In a Zepbound trial of people with type 2 diabetes, it affected 10.3% of those also taking a sulfonylurea. It affected 2.1% of those who were not.1

The US labels carry a boxed warning because tirzepatide and semaglutide caused thyroid C-cell tumours in rodent studies. Whether they do in humans is unknown.1,2 They are not for people with a personal or family history of medullary thyroid cancer or MEN 2.1 The EU Wegovy label adds NAION, an eye condition that can cause sudden loss of vision. In people with type 2 diabetes, studies suggest about one extra case per 10,000 person-years of treatment. For example, that is 10,000 people treated for one year.4 Tirzepatide slows stomach emptying. So the US Zepbound label asks patients to tell their healthcare team before planned surgery or deep sedation.1 The EU Wegovy label flags the same risk for semaglutide.4

What do people on GLP‑1 medicines report about side effects?

From public patient forums: 55 Reddit threads in r/Zepbound, r/mounjarouk, r/Ozempic, r/WegovyWeightLoss, r/glp1 and r/Mounjaro, read from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Not studied Many say they had no side effects or only mild ones, and several note that people without problems rarely post.
  • Matches the label Many describe nausea, sometimes with vomiting, that is worst in the first weeks and after a dose increase.1,3
  • Matches the trial Many say constipation is the problem that lasts longest.5
  • Matches the label Many mention burping, reflux, bloating or wind.1
  • Matches the label Many report tiredness, often at the start or after a dose increase.1,4
  • Matches the label Many notice hair shedding, which they often put down to fast weight loss.1,2

Advice people share

  • Matches the label Many advise drinking more fluids, especially after diarrhoea.6
  • Matches the label Many suggest moving up slowly or staying on a lower dose, and several say to agree this with the prescriber. The US Zepbound label says the prescriber may consider a lower maintenance dose if a dose is not tolerated.1
  • Not studied Many suggest small, slow, low-fat meals. We found no trial testing this.
  • Label says otherwise Several posts describe taking self-chosen part doses. The labels give these medicines as the prescribed dose, once a week.1,2

In your country

Every label we opened lists the same common stomach side effects and serious warnings. What differs is the brands sold and whether the label mentions the eye condition NAION.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The Australian Mounjaro Product Information lists post-marketing reports of NAION in people using GLP‑1 medicines. NAION is a rare cause of vision loss.8

Emergency number: 000

Side effects and risks in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: The Canadian Zepbound monograph warns about NAION with tirzepatide too. Sudden loss of vision should be referred urgently for an eye examination.7

Emergency number: 911

Side effects and risks in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The answer above applies.

Emergency number: 15 or 112

Side effects and risks in France

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 112

Side effects and risks in Germany

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We found no public Indian label to open, so this page relies on the US and EU labels. They list the same common side effects and serious warnings.

Emergency number: 112

Side effects and risks in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a Saudi label for this page, so it relies on the US and EU labels. They list the same common side effects and serious warnings.

Emergency number: 997 or 911

Side effects and risks in Saudi Arabia

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a UAE label for this page, so it relies on the US and EU labels. They list the same common side effects and serious warnings.

Emergency number: 998 for an ambulance, or 999

Side effects and risks in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 999

Side effects and risks in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The US Zepbound and Wegovy labels we opened do not list NAION; the rest of the answer above applies.1,2

Emergency number: 911

Side effects and risks in the US

Get help now: call your local emergency number for any sudden or severe pain, severe or persistent vomiting or diarrhoea, fainting or difficulty breathing,9 or swelling of the tongue or throat, or difficulty swallowing.10 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if nausea, vomiting or diarrhoea does not go away. Do the same for upper stomach pain, fever, yellow skin or eyes, clay-coloured stools or vision changes.6 Severe stomach pain that will not go away may be felt through to the back. For this, the US Mounjaro Medication Guide says to stop the medicine and call right away.6

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Eli Lilly. Zepbound (tirzepatide) US prescribing information. Boxed warning and sections 2.1, 5, 6.1. pi.lilly.com
  2. Novo Nordisk. Wegovy (semaglutide) US prescribing information. Boxed warning and sections 2, 5, 6.1. dailymed.nlm.nih.gov
  3. European Medicines Agency. Mounjaro summary of product characteristics (EU label), section 4.8. ema.europa.eu
  4. European Medicines Agency. Wegovy summary of product characteristics (EU label), sections 4.4 and 4.8. ema.europa.eu
  5. Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. STEP 1-4 trials funded by Novo Nordisk. PMC9293236
  6. Eli Lilly. Mounjaro US Medication Guide. pi.lilly.com
  7. Zepbound (tirzepatide injection) Canadian Product Monograph, section 7. pdf.hres.ca
  8. Mounjaro Australian Product Information, section 4.8. medsinfo.com.au
  9. American College of Emergency Physicians. Know When to Go. emergencyphysicians.org
  10. American College of Emergency Physicians. Allergies and Anaphylaxis. emergencyphysicians.org
  11. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025. Table 3. Funded by Eli Lilly. doi.org

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked between Nov 9 and Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write